These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16857615)

  • 1. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls.
    Bergersen BM; Schumacher A; Sandvik L; Bruun JN; Birkeland K
    Scand J Infect Dis; 2006; 38(8):682-9. PubMed ID: 16857615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome.
    Gazzaruso C; Bruno R; Garzaniti A; Giordanetti S; Fratino P; Sacchi P; Filice G
    J Hypertens; 2003 Jul; 21(7):1377-82. PubMed ID: 12817187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.
    Blass SC; Ellinger S; Vogel M; Ingiliz P; Spengler U; Stehle P; von Ruecker A; Rockstroh JK
    Eur J Med Res; 2008 May; 13(5):209-14. PubMed ID: 18559303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy.
    Palacios R; Santos J; González M; Ruiz J; Márquez M
    Int J STD AIDS; 2007 Mar; 18(3):184-7. PubMed ID: 17362552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.
    Lemoine M; Barbu V; Girard PM; Kim M; Bastard JP; Wendum D; Paye F; Housset C; Capeau J; Serfaty L
    AIDS; 2006 Feb; 20(3):387-95. PubMed ID: 16439872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
    Estrada V; Martínez-Larrad MT; González-Sánchez JL; de Villar NG; Zabena C; Fernández C; Serrano-Ríos M
    Metabolism; 2006 Jul; 55(7):940-5. PubMed ID: 16784968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperglycosylated ferritin in sera of HIV-1-infected patients treated with highly active antiretroviral therapy.
    Malvoisin E; Livrozet JM; Ducluzeau PH; Makloufi D; Cohen R; Vincent N
    AIDS; 2006 Feb; 20(3):457-9. PubMed ID: 16439882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
    Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
    HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.
    Bonfanti P; De Socio GV; Ricci E; Antinori A; Martinelli C; Vichi F; Penco G; Madeddu G; Orofino G; Valsecchi L; Rusconi S; Menzaghi B; Pocaterra D; Quirino T
    Biomed Pharmacother; 2012 Jul; 66(5):348-53. PubMed ID: 22705335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage.
    Bezante GP; Briatore L; Rollando D; Maggi D; Setti M; Ghio M; Agosti S; Murdaca G; Balbi M; Barsotti A; Cordera R
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):277-82. PubMed ID: 19422999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.